公开(公告)号：US20200171092A1

公开(公告)日：2020-06-04

申请号：US16620655

申请日：2018-05-08

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Hayato Kurata ,  Kotoe Tamada ,  Hiroyuki Nishida

IPC: A61K35/28 ,  A61K9/14 ,  A61K38/20 ,  A61K38/18 ,  A61K38/17 ,  A61P9/10

Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

公开(公告)号：US20180344775A1

公开(公告)日：2018-12-06

申请号：US15778362

申请日：2016-11-17

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Hayato Kurata ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61P1/16 ,  C12N5/0775

CPC classification number: A61K35/28

Abstract: An object of the present invention is to provide a method for producing a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue, which is excellent in convenience in preparation of a therapeutic agent while maintaining an excellent therapeutic effect on the stromal cells derived from adipose tissue against liver diseases, and a therapeutic agent for liver diseases obtained by such a producing method. The present invention is directed to a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue which has been subjected to both cryopreservation and thawing at least twice.